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Regenerative Medicine Strategies for Hypoplastic
Left Heart Syndrome
Josue Chery, MD,1 Joshua Wong, MD,2 Shan Huang,1 Shuyun Wang, MD, PhD,1 and Ming-Sing Si, MD1
Hypoplastic left heart syndrome (HLHS), the most severe and common form of single ventricle congenital heart
lesions, is characterized by hypoplasia of the mitral valve, left ventricle (LV), and all LV outflow structures.
While advances in surgical technique and medical management have allowed survival into adulthood, HLHS
patients have severe morbidities, decreased quality of life, and a shortened lifespan. The single right ventricle
(RV) is especially prone to early failure because of its vulnerability to chronic pressure overload, a mode of
failure distinct from ischemic cardiomyopathy encountered in acquired heart disease. As these patients enter
early adulthood, an emerging epidemic of RV failure has become evident. Regenerative medicine strategies
may help preserve or boost RV function in children and adults with HLHS by promoting angiogenesis and
mitigating oxidative stress. Rescuing a RV in decompensated failure may also require the creation of new,
functional myocardium. Although considerable hurdles remain before their clinical translation, stem cell
therapy and cardiac tissue engineering possess revolutionary potential in the treatment of pediatric and adult
patients with HLHS who currently have very limited long-term treatment options.
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Introduction
Hypoplastic left heart syndrome: definition, epidemiology,
and current clinical management
S ingle ventricle heart disease is a spectrum of con-genital heart defects defined by hypoplasia of the right
ventricle (RV) or left ventricle (LV), leaving only one ef-
fective pumping chamber to deliver blood flow to both
pulmonary and systemic vasculature. Hypoplastic left heart
syndrome (HLHS), the most common form of single ven-
tricle heart disease, is characterized by hypoplasia of the
mitral valve, LV, and LV outflow structures, which include
the aortic valve, ascending aorta, and aortic arch. In HLHS,
blood flow into the aorta is dependent on cardiac output
generated by the RV passing through the patent ductus ar-
teriosus, a normal fetal structure that connects the pulmo-
nary artery to the aorta. Without intervention, HLHS is
uniformly fatal during infancy either from closure of the
patent ductus arteriosus or shock due to exuberant blood
flow to the lungs and insufficient blood flow to the body.
While the incidence of HLHS is 0.016–0.036% of all live
births, it is responsible for up to 23% of cardiac deaths
during the first week of life and 15% of cardiac deaths
within the first month of life if left untreated.1–3 Three-stage
palliative surgeries have been the mainstay of treatment for
infants born with HLHS since the early 1980s, culminating
in the total cavopulmonary anastomosis, or the Fontan
procedure, performed at 2–3 years of age.4 Upon completion
of the Fontan, the arterial and venous circulations are con-
nected in series with the RV providing the lone driving force
for systemic blood flow while venous blood drains passively
into the lungs.
Results of current clinical management of HLHS
Although advances in surgical technique and medical
management have improved survival into adulthood, HLHS
patients suffer decreased quality of life and extensive reli-
ance on medical care due to severe morbidities, including
chronic RV failure. One third of these patients die by 25
years of age from end-stage RV failure.5–7 This number will
undoubtedly increase as more and more patients survive past
childhood and represents an emerging epidemic. Heart
transplantation remains the only long-term treatment option
for HLHS patients with RV failure and is unfortunately far
from an optimal treatment due to the shortage of donor
organs, need for immunosuppression, and limited lifespan of
the allograft.8,9 Thus, there is a dire need for novel ap-
proaches to preserve and improve the function of the sys-
temic RV, as emphasized recently in a report from a
National Heart, Lung, and Blood Institute Working Group.10
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The purpose of this review is to introduce HLHS, highlight
the mechanisms of RV failure, and review various regener-
ative medicine approaches and their rational implementation
for treating the failing RV in this important clinical entity.
Heart failure in HLHS: key vulnerabilities
in the pressure-overloaded RV
In the normal heart, the RV pressures are *20% of sys-
temic arterial (and LV) blood pressure. In HLHS, the RV is
required to generate systemic arterial blood pressures during
the patient’s entire lifetime and is, therefore, prone to early
failure.5,11,12 Pressure loading creates increased work and
stress for the RV. The normalmyocardial response to pressure
overload is myocyte hypertrophy accompanied by angio-
genesis and increased antioxidant enzyme activity to mitigate
damage from increased oxidative stress encountered in this
setting.13–17 Recent evidence has revealed that the RV is
disadvantaged compared with the LV in its molecular adap-
tation to pressure overload. The angiogenic response in a
pressure-overloaded RV is diminished and has been docu-
mented in HLHS and pulmonary hypertension.18–22 This
blunted angiogenic response is believed to lead to an inadequate
supply of oxygen and nutrients, thereby causing cardiomyocyte
dysfunction. Furthermore, the antioxidant response in the RV is
also diminished, thusmaking themyocardiummore susceptible
to oxidative injury during pressure loading.23–25
Consistent with these molecular mechanisms is strong
clinical evidence that the RV does not adapt well to chronic
systemic afterload in HLHS.10,12,26–28 Therefore, designing
regenerative therapies to preserve RV function in HLHS
should target both myocardial angiogenesis and oxidative
stress. Furthermore, in HLHS patients with advanced stages
of RV failure, irreversible damage from chronic ischemia
and oxidative injury result in a reduction in the total number
of cardiomyocytes. In this situation, regenerative medicine
approaches would need to increase the number of viable
cardiomyocytes as well as provide a blood vessel network to
support this new myocardium.
Regenerative Medicine Strategies For HLHS
Regenerative medicine approaches to promote myocardial
angiogenesis in the pressure-overloaded RV
The normal response to pressure overload is myocyte hy-
pertrophy accompanied by angiogenesis13–15 and upregula-
tion of angiogenic signals such as vascular endothelial growth
factor A (VEGFA) and angiopoietin-2.29 Chronic pressure
overload leads to a maladaptive diminution or rarefaction of
capillary density.30–32 Capillary rarefaction causes ischemia
and progression to decompensated heart failure.33,34 Various
clinical conditions such as hypertension, aortic stenosis, and
hypertrophic obstructive cardiomyopathy lead to pressure
overload of the LV and result in capillary rarefaction.35–37
The RV is also pressure overloaded and subject to capillary
rarefaction in diseases such as HLHS and pulmonary hyper-
tension.18–20 There is strong clinical evidence that the RV
does not adapt well to chronic systemic afterload in HLHS,
consistent with the progression and sequela of capillary
rarefaction.10,12,26–28
Promoting angiogenesis has been shown to prevent LV
heart failure in the setting of hypertrophy.38,39 A variety of
stem cells, including mesenchymal stem cells (MSCs),
resident cardiac stem/progenitor cells (CPCs), and endo-
thelial progenitor cells (EPCs), have been demonstrated to
stimulate myocardial angiogenesis. Most of these cell ther-
apies have been evaluated for use in LV ischemic heart
disease, but are included in our discussion here.
MSCs are believed to reside in the perivascular regions of
essentially all tissues and are comprised of a heterogeneous
population of plastic adherent cells that do not possess a
unique surface marker phenotype.40 It is well recognized
that MSCs are proangiogenic and secrete numerous angio-
genic growth factors.41–49 Multiple paracrine and juxtacrine
mechanisms exist, by which MSCs promote angiogenesis,
indicating a complex and regulated process that is superior to
the indiscriminate, forced expression of an angiogenic gene
such as VEGFA in the myocardium.50–52 Therefore, MSC
therapy provides an approach to therapeutic angiogenesis that
cannot be replicated by other noncell therapy strategies. Fur-
thermore, MSCs have been demonstrated to possess the ability
to differentiate into endothelial cells during 3D culture orwhen
exposed to VEGFA or sphingosine-1-phosphate.53–55
MSCs are being evaluated as a therapeutic agent for
promoting angiogenesis in various ischemic conditions, but
have not been specifically evaluated in the setting of RV
pressure-overload hypertrophy.56–64 The success of MSCs in
treating ischemic conditions depends on their inherent
proangiogenic characteristics, and thus numerous investi-
gators have sought to enhance the ability of MSCs to pro-
mote angiogenesis by augmenting the expression of various
angiogenic signals in these cells.65–70 However, genetically
modified MSCs face extensive and protracted safety and
regulatory hurdles before clinical use, and thus the identi-
fication of the most potent proangiogenic MSC sources or
subtypes is currently preferable for the most direct pathway
to clinical translation. Several studies have examined the
proangiogenic potency of MSCs isolated from different
tissue sources and ages of tissue source. MSCs derived from
adipose, bone marrow, myocardium, and skeletal muscle are
all equivalent in promoting angiogenesis.71,72 MSCs from
other clinically relevant sources, such as umbilical cord,
placenta, thymus, and sternum have not been comparatively
evaluated in their ability to promote angiogenesis.73–79
While the influence of MSC tissue source is unclear, it is
evident from existing data that MSCs derived from younger,
healthy subjects are more potent in promoting angiogene-
sis.80–82 Yet another approach to increasing the proangio-
genic potency of MSCs is to precondition them with
hypoxia, growth factors, and small molecules.83–86 Ulti-
mately, selection and preparation of the ideal proangiogenic
MSC therapeutic product will depend upon ease of isolation,
availability of neonatal source tissue, ability to expand these
cells, and finding an optimal preconditioning approach.
Cardiac stem/progenitor cells, a subset of stem cells that
reside within the myocardium, have the potential to differ-
entiate into cardiomyocytes, smooth muscle cells, and en-
dothelial cells. Injection of exogenous CPCs into models of
ischemic heart disease has been shown to exert a paracrine
effect that promotes angiogenesis, protect existing cardio-
myocytes, and stimulate endogenous CPCs to potentially
enhance regeneration.87–91 Although no experimental evi-
dence exists of whether CPCs can improve angiogenesis in
the pressure-overloaded RV, there is some experience that
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these cells may promote angiogenesis in the pressure-
overloaded LV. Mice receiving intravenous administration
of CPCs after transverse aortic constriction (a model of LV
pressure overload) resulted in increased expression of an-
giogenic growth factors (such as bFGF) and density of
CD31+ endothelial cells.92 Cardiac progenitor cells can be
isolated from neonates undergoing open heart surgery;
however it is unclear whether clinically relevant amounts of
these cells can be harvested for patient therapy.93 Currently,
there is no evidence that CPCs improve angiogenesis in a
pressure-overloaded RV.
EPCs belong to a subset of bone marrow-derived cells
that are found in the peripheral circulation and aid in en-
dothelial homeostasis as well as angiogenesis. EPCs dif-
ferentiate into endothelial cells through the activation of an
upstream, highly conserved regulator gene named hetero-
chromatin protein 1 alpha (HP1a). Subsequently, a multi-
cellular process ensues that initiates sprouting to culminate
in angiogenesis.94,95 While the complex biology of EPCs
has yet to be fully understood, an inverse correlation be-
tween the absolute number of EPCs and cardiovascular
risk factors and disease has been elucidated.96–98 This has
been corroborated by preclinical and clinical studies that
demonstrate an improvement in LV function with EPC
therapy in the setting of ischemic heart disease.99,100 The
precise role of EPCs in pressure overload-induced RV
failure and potential therapy for this distinct entity has yet
to be defined, although some evidence exists that endog-
enous EPCs are mobilized in experimental models of LV
pressure overload.101,102
Human umbilical cord blood-derived mononuclear cells
(UCBMNCs) were recently described to promote angiogen-
esis in the pressure-overloaded RV in athymic nude mice.103
Human UCBMNCs were injected into the RV 4 weeks after
pulmonary artery banding, and animals were euthanized at 8
weeks for histological analysis. Therapy with UCBMNCs
resulted in a significantly increased RV myocardial capillary
density as compared with untreated controls. Recent evidence
indicates that culturing UCBMNCs for 2 weeks yields a
heterogeneous collection of cells that is comprised of EPCs
and MSCs, but it is unknown if having this combination of
both these cell types yield an additive or synergistic proan-
giogenic effect.104
There is convincing evidence that a variety of stem cells
can promote angiogenesis in the heart, although most of
these findings were obtained in models of acute myocardial
ischemia. Further research is needed to determine the ability
of these stem cells to promote angiogenesis in the pressure-
overloaded RV. The magnitude of therapeutic effect is
likely related to the intrinsic proangiogenic potency, and
thus identifying a stem cell with especially potent proan-
giogenic characteristics is important.
Scaffold therapy for HLHS
Acellular scaffolds are made from synthetic polymers or
human or animal extracellular matrix and can be adminis-
tered in patch form to the appropriate myocardial site and
can serve as a platform for endogenous progenitor cell mi-
gration and proliferation. Short-term results of both animal
models and clinical studies using the FDA-approved porcine
small intestinal submucosa (pSIS) demonstrate that the
material is suitable for closure of septal defects. However,
an inflammatory response with fibrosis is generated without
site-specific tissue growth. Moreover, in the pediatric pop-
ulation, pSIS is associated with vessel stenosis and a sub-
optimal aortic valve repair.105–108
Clinical experience with acellular scaffolds suggests that
the scaffolds do not regenerate site-specific tissue. Fur-
thermore, they stimulate very little regenerative response
for the myocardium, which limits their use as sole therapy.
An alternative approach to promote regeneration is to
combine acellular scaffolds with stem cell therapy. The
scaffolds can serve as a delivery vehicle for stem cells and
also prime the stem cells for angiogenesis and regenera-
tion. When pSIS is seeded with either MSCs or CPCs, the
stem cells proliferate and differentiate to display early car-
diogenic profile.109 Another approach that is currently being
investigated is to convert the extracellular matrix scaffolds
into a hydrogel that can be directly injected, with or without
stem cells, into the ischemic myocardium.110–113 Other types
of hydrogels have also been described and have been sup-
plemented with stromal cell-derived factor 1a (SDF1a), an-
giogenic peptides, and other instructive growth factors to
promote angiogenesis.114–118 Preclinical evaluation of acel-
lular scaffolds and injectable hydrogels in small and large
animal models of ischemic heart disease has demonstrated
efficacy and promotion of angiogenesis. They have not been
evaluated in an RV pressure-overload model of heart failure,
so its relevance to HLHS is unknown.
Regenerative medicine approaches to alleviate oxidative
stress in the pressure-overloaded RV
Although there are no studies specifically evaluating
the utility of regenerative medicine approaches to mitigate
oxidative injury in the pressure-overloaded RV, there is
strong experimental evidence which demonstrates that a
variety of stem cells can provide antioxidative benefit.
Endogenous mechanisms to mitigate damage from oxida-
tive stress are largely dependent on antioxidant enzymes.
The enzyme superoxide dismutase (SOD) is important in
its role as part of an antioxidative defense mechanism in
all cells. It catalyzes the dismutation of the damaging
superoxide (O2
-) free radical into less damaging H2O2.
There are three isoforms of SOD: SOD1, 2, and 3. SOD1 is
located in the cytosol and uses copper and zinc. SOD2
is located in the mitochondria and uses manganese. SOD3
is secreted into the extracellular space and uses copper and
zinc. Extracellular SOD3 has been demonstrated to blunt
tissue damage and inflammation.119–121 Because it is se-
creted, SOD3 is a potential mediator of the antioxidative
property observed in stem cells.
Yang et al. determined that EPCs secrete unidentified
soluble factors that protect endothelial cells against oxidative
stress, thereby increasing survival and cellular function.122
Bone marrow-derived EPCs have also been demonstrated to
have therapeutic effects in a dilated cardiomyopathymodel in
rats with streptozotocin-induced diabetes, and that these
beneficial effects are associated with increased expression of
SOD2 and decreased apoptosis and fibrosis.123 Qiu et al.
determined that EPCs protect against cerebral ischemia–
reperfusion injury in rats, and this therapeutic effect was as-
sociated with increased total SOD activity, increased levels of
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the nonenzymatic scavenger, glutathione, and decreased ap-
optosis in the affected areas.124
MSCs have been shown to possess antioxidative effects,
which are mediated by extracellular SOD3. DeSantiago et al.
determined that mouse bone marrow MSCs protect mouse
ventricular cardiomyocytes from ischemia–reperfusion injury
in vitro by secretion of SOD3, which can reduce the levels
of damaging reactive oxygen species (ROS).125 Arslan et al.
determined that exosomes secreted by MSCs possess anti-
oxidative properties in a murine model of cardiac ischemia–
reperfusion injury.126 These investigators found that only
intact exosomes could improve cardiac function, reduce
oxidative stress, and restore bioenergetics after myocardial
ischemia–reperfusion injury.
Forced expression of SOD3 in bone marrow-derived
MSCs may lead to enhanced therapeutic effects.127 Bone
marrow MSCs infected with adenovirus-containing SOD3
had a significantly higher survival after transplantation and
could provide sustained SOD3 production. This enhanced
SOD3 expression was accompanied with a reduction of
myocardial infarction-induced oxidative stress, improve-
ment of cardiac function, reduction of fibrosis, and apoptosis
after myocardial infarction in rodents. In vitro, bone marrow
MSCs expressing SOD3 attenuated cardiomyocyte apoptosis
and ROS production and enhanced cardiomyocyte prolifer-
ation after hypoxia/serum deprivation.
These results indicate that EPCs and MSCs do possess the
ability to neutralize oxidative stress, and that they may pro-
vide benefit in mitigating oxidative injury in the pressure-
overloaded RV. Stem cells with forced or intrinsically high
expression of SOD3 may effectively preserve RV function in
HLHS and thus deserve further investigation.
Regenerative medicine approaches to creating
new myocardium
Perhaps one of the boldest and most exciting regenerative
medicine approaches to heart failure is the possibility of
creating functional heart tissue patches or ventricles in vitro
for implantation in patients. Enlarging the LV with en-
gineered heart tissue (EHT) has even been proposed for pa-
tients with HLHS.128 However, to create a useable LV would
require more than adding myocardium to increase LV vol-
ume. It would necessitate the creation of a mitral valve, aortic
valve, and ascending aorta. Hence curing HLHS by using the
tissue engineering approach is a significant challenge that
would entail the in vitro creation of functional heart valves,
myocardium, and larger arteries.
However, leaving palliated patients with their single
ventricle (Fontan) physiology and improving the contractile
function of the pressure-overloaded RV would be clinically
feasible and perhaps more achievable from a tissue engi-
neering standpoint. EHT would be of benefit in HLHS pa-
tients with advanced stages of RV failure and ideally augment
cardiac output immediately upon implantation. To fabricate
EHT that would accomplish this feat, a large number of
contractile human ventricular cardiomyocytes organized in a
compact arrangement and supplied by a dense, perfused
vascular network is required.
With embryonic stem cells, the advent of induced plu-
ripotent stem cells (iPSCs), and further molecular insights
into heart development, derivation of large numbers of
human cardiomyocytes is now possible.129 One of the key
remaining challenges on this front is creating and arranging
pure ventricular-type cardiomyocytes, and then arranging
these millions to billions of cardiomyocytes, along with fi-
broblasts, smooth muscle cells, and endothelial cells into
the compact, organized fashion seen in native myocar-
dium. Such a construct would require a mature and per-
fused vasculature to provide the obligatory flow of nutrients
and oxygen to supply the cardiomyocytes, especially those
deep to the surface of the construct beyond the oxygen
diffusion distance.130,131 A functioning, perfused microcir-
culation is paramount, without which central necrosis is
observed in tissues greater than 100mm in thickness.132 The
vascularization problem is one of the most important bot-
tlenecks in the field of tissue engineering as it is otherwise
not possible to create adequately sized, functional replace-
ment tissues.
The vasculature of EHT must be multiscalar and multi-
phenotype to properly distribute energy and mass flow to
parenchymal cardiomyocytes. As in the architecture of the
native terminal vascular bed, the engineered vascular network
must contain a perfused artery (‡4mm diameter), arterioles
(10–200 mm), capillaries (4–10 mm), venules (10–200 mm),
and a draining vein (‡4mm) to optimally accomplish their
function. The artery and vein must also be at least several
millimeters in diameter to make surgical anastomosis to
the patient’s native vascular network possible.
Most research thus far has focused on the creation of
microvasculature in EHT. Most in vitro approaches have
incorporated the coculture of cardiomyocytes and endothe-
lial cells with EPCs, fibroblasts, or MSCs.133–135 The density
of the engineered microvasculature in these EHT constructs
are generally at least one order of magnitude less than the
capillary density present in native myocardium (5000/mm2).
Thus, the thickness of constructs is currently still constrained
because the relatively sparse engineered microvasculature
lacks perfusion and, therefore, the EHT construct thickness is
limited by oxygen diffusion limitations.
There have been recent descriptions of methods to perfuse
engineered macro- and microvasculature. Since their semi-
nal description of the perfusion–decellularization method of
rat hearts to obtain scaffolds that were then seeded with
neonatal rat cardiomyocytes, the group led by Ott has re-
cently followed up with a study of decellularizing human
hearts and reseeding with cardiomyocytes derived from
human iPSCs.136,137 In this method, the scaffold for the
native multiscale vascular network is also left intact, and
thus can be used to perfuse seeded cardiomyocytes. Fur-
thermore, these investigators have seeded endothelial cells
into this perfusable vascular network in an attempt to rec-
reate a living vasculature.136 The ultimate success of this
strategy to create a vascularized heart tissue (or even entire
hearts) is still unclear as the resistance of the endothelial
cell-seeded vascular network to the development of throm-
bosis has not been rigorously studied.
Another ingenious approach that partially borrows from
the multiscale vascular bed of native tissue was recently
described by Sekine et al.138 A pedicle tissue flap based off
the femoral vessels of the rat was used as a perfusable tissue
bed and serially applied cardiomyocyte cell sheets were then
juxtaposed to this perfused vascular bed to generate a thick,
vascularized, and perfused EHT construct. This approach
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appears to have great potential, but has yet to be applied to
human-derived tissues and EHT.
Perfused engineered vascular networks that do not rely on
living or decellularized tissues have been generated with
microfluidics technology and 3D bioprinting.139,140 These
are interesting, ‘‘bottom up’’ engineering approaches to
developing perfusable vasculature since they do not require
the presence of native vasculature. The microfluidics ap-
proach also utilizes the self-organizing ability of human
endothelial cells and yields perfusable capillary networks
onto which cardiomyocytes can be seeded to yield in vitro
models of heart tissue.139,141 Expanding this approach to in-
clude the generation and incorporation of larger (surgically-
implantable) vessels has yet to be described. Dai’s group
described the use of 3D bioprinting to create millimeter scale
endothelial cell-lined channels in collagen hydrogels, which
were also seeded with endothelial cells.140 They generated
two perfusable endothelial cell-lined bioprinted chan-
nels connected by a capillary network formed from self-
organizing endothelial cells between these two channels,
resulting in a multiscale, perfusable vascular network. Al-
though vascular communication between the two perfusable
larger channels was not demonstrated and cardiomyocytes
were not included as parenchymal cells in this engineered
vascular network, this is a promising approach to developing
EHT with a multiscale, perfusable vascular network.
Stem cell therapy clinical trials for HLHS
The discovery of cardiomyocyte apoptosis in physiologic
states implies that the creation of new cardiomyocytes is
necessary to maintain homeostasis.142,143 This regenerative
process may be mediated by CPCs.142 While children have a
greater quantity of CPCs, the absolute number is not suffi-
cient to correct the anatomic derangements seen in HLHS.93
However, these limited cells can be harvested, differenti-
ated, amplified, and potentially used clinically.144,145 The
precise identification of CPCs has evaded the field. For
example, these resident cardiac stem cells can be defined by
a surface marker (such as c-kit) or can be defined by its
method of derivation, as in the case for cardiosphere-derived
cells, a more heterogeneous population of cells.146 The
phase I clinical trials SCIPIO and CADUCEUS utilized
CPCs as treatment for adult-onset, acquired ischemic car-
diomyopathy, and results of these trials demonstrated im-
proved LV function and decreased fibrosis.145,147
In HLHS patients, the phase I clinical trial TICAP, in-
vestigated the use of autologous CPCs, obtained either at the
second or third-stage procedure, delivered into the coronary
arteries. There were no complications or tumor formation
reported within 36 months of CPC administration. More-
over, a clinical improvement of RV ejection fraction and a
reduction in brain natriuretic peptide, a biomarker for heart
failure, was seen. Currently, a Phase II clinical trial is un-
derway and will examine the effects of CPCs on RV ejection
fraction and myocardial fibrosis in more detail.93,148–151
Initial use of bone marrow-derived stem cells in the pe-
diatric population with end-stage heart failure was first de-
scribed through case reports performed for management of
dilated cardiomyopathy and RV failure in HLHS.152–154
These initial descriptions reported modest improvement in
ventricular function and heart failure symptoms based on
New York Heart Association classification.151,153,154 How-
ever, the benefits were short lived. Moreover, the patients
were concurrently treated with sildenafil and erythropoietin,
two drugs known to mobilize progenitor cells, as potential
confounders in the perceived effects. Recently, Burkhart
et al. reported on the safety of intramyocardial injection of
autologous umbilical blood-derived cells during the second
palliative procedure of a patient with HLHS.155 Confound-
ing factors such as deviations in medical and surgical
treatment made it difficult to attribute the clinical benefits to
stem cell therapy alone. Regardless, these case reports
highlight the potential benefit of stem cell therapy in pedi-
atric heart disease, although more research is needed to
optimize stem cell therapy for those with HLHS.
Conclusions
Improvement in the treatment of HLHS has increased
survival of some children into adulthood. Nevertheless, the
high morbidity and mortality associated with HLHS remains
unsatisfactory with an emerging epidemic of RV failure in
these patients with no available alternative treatment op-
tions. This challenging clinical scenario presents as an ideal
situation where regenerative medicine approaches can be
applied. Promising preclinical and early clinical evidence
suggest that stem cell therapy may be able to preserve the
function of the pressure-overloaded RV. Initial case reports
and subsequent clinical trials highlight the potential benefits
of regenerative medicine in patients with HLHS, while re-
minding us of the challenges that remain to be conquered.
Consequently, further research is required to develop and
establish regenerative medicine therapies in the armamen-
tarium of the clinical treatment of HLHS.
Disclosure Statement
No competing financial interests exist.
References
1. Samanek, M., Slavik, Z., Zborilova, B., Hrobonova, V.,
Voriskova, M., and Skovranek, J. Prevalence, treatment,
and outcome of heart disease in live-born children: a
prospective analysis of 91,823 live-born children. Pediatr
Cardiol 10, 205, 1989.
2. Fyler, D.C., Rothman, K.J., Buckley, L.P., Cohn, H.E.,
Hellenbrand, W.E., and Castaneda, A. The determinants
of five year survival of infants with critical congenital
heart disease. Cardiovasc Clin 11, 393, 1981.
3. Morris, C.D., Outcalt, J., and Menashe, V.D. Hypoplastic
left heart syndrome—natural-history in a geographically
defined population. Pediatrics 85, 977, 1990.
4. Norwood, W.I., Lang, P., and Hansen, D.D. Physiologic
repair of aortic atresia-hypoplastic left heart syndrome. N
Engl J Med 308, 23, 1983.
5. d’Udekem, Y., Iyengar, A.J., Galati, J.C., Forsdick, V.,
Weintraub, R.G., Wheaton, G.R., Bullock, A., Justo, R.N.,
Grigg, L.E., Sholler, G.F., Hope, S., Radford, D.J., Gen-
tles, T.L., Celermajer, D.S., and Winlaw, D.S. Redefining
expectations of long-term survival after the Fontan pro-
cedure: twenty-five years of follow-up from the entire
population of Australia and New Zealand. Circulation
130, S32, 2014.
REGENERATIVE MEDICINE AND HYPOPLASTIC LEFT HEART SYNDROME 463
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
6. Iyengar, A.J., Winlaw, D.S., Galati, J.C., Wheaton, G.R.,
Gentles, T.L., Grigg, L.E., Justo, R.N., Radford, D.J.,
Weintraub, R.G., Bullock, A., Celermajer, D.S., and
d’Udekem, Y. The extracardiac conduit Fontan procedure
in Australia and New Zealand: hypoplastic left heart
syndrome predicts worse early and late outcomes. Eur J
Cardiothorac Surg 46, 465, 2014.
7. Arnold, R.R., Loukanov, T., and Gorenflo, M. Hypoplastic
left heart syndrome—unresolved issues. Front Pediatr 2,
125, 2014.
8. Chinnock, R.E., and Bailey, L.L. Heart transplantation for
congenital heart disease in the first year of life. Curr
Cardiol Rev 7, 72, 2011.
9. Bailey, L.L., Nehlsen-Cannarella, S.L., Doroshow, R.W.,
Jacobson, J.G., Martin, R.D., Allard, M.W., Hyde, M.R.,
Dang Bui, R.H., and Petry, E.L. Cardiac allotransplanta-
tion in newborns as therapy for hypoplastic left heart
syndrome. N Engl J Med 315, 949, 1986.
10. Bernstein, D. Introduction to the series: challenges and
opportunities in pediatric heart failure and transplantation.
Circulation 129, 112, 2014.
11. Si, M.S., Pearson, G.D., and Ohye, R.G. Shunt choice in
single right ventricle patients: an update. Expert Rev
Cardiovasc Ther 11, 1691, 2013.
12. Tham, E.B., Smallhorn, J.F., Kaneko, S., Valiani, S.,
Myers, K.A., Colen, T.M., Kutty, S., and Khoo, N.S. In-
sights into the evolution of myocardial dysfunction in the
functionally single right ventricle between staged pallia-
tions using speckle-tracking echocardiography. J Am Soc
Echocardiogr 27, 314, 2014.
13. Hudlicka, O., Brown, M., and Egginton, S. Angiogenesis
in skeletal and cardiac-muscle. Physiol Rev 72, 369, 1992.
14. Souders, C.A., Borg, T.K., Banerjee, I., and Baudino, T.A.
Pressure overload induces early morphological changes in
the heart. Am J Pathol 181, 1226, 2012.
15. Tomanek, R.J., and Torry, R.J. Growth of the coronary
vasculature in hypertrophy: mechanisms and model de-
pendence. Cell Mol Biol Res 40, 129, 1994.
16. Kai, H., Mori, T., Tokuda, K., Takayama, N., Tahara, N.,
Takemiya, K., Kudo, H., Sugi, Y., Fukui, D., Yasukawa,
H., Kuwahara, F., and Imaizumi, T. Pressure overload-
induced transient oxidative stress mediates perivascular
inflammation and cardiac fibrosis through angiotensin II.
Hypertens Res 29, 711, 2006.
17. Sag, C.M., Santos, C.X., and Shah, A.M. Redox regulation
of cardiac hypertrophy. J Mol Cell Cardiol 73, 103, 2014.
18. Drake, J.I., Bogaard, H.J., Mizuno, S., Clifton, B., Xie, B.,
Gao, Y., Dumur, C.I., Fawcett, P., Voelkel, N.F., and
Natarajan, R. Molecular signature of a right heart failure
program in chronic severe pulmonary hypertension. Am J
Respir Cell Mol Biol 45, 1239, 2011.
19. Padalino, M.A., Castellani, C., Toffoli, S., Della Barbera,
M., Milanesi, O., Thiene, G., Stellin, G., and Angelini, A.
Pathological changes and myocardial remodelling related
to the mode of shunting following surgical palliation for
hypoplastic left heart syndrome. Cardiol Young 18, 415,
2008.
20. Salih, C., Sheppard, M.N., and Ho, S.Y. Morphometry of
coronary capillaries in hypoplastic left heart syndrome.
Ann Thorac Surg 77, 903, 2004.
21. Ryan, J.J., and Archer, S.L. The right ventricle in pul-
monary arterial hypertension: disorders of metabolism,
angiogenesis and adrenergic signaling in right ventricular
failure. Circ Res 115, 176, 2014.
22. Sutendra, G., Dromparis, P., Paulin, R., Zervopoulos, S.,
Haromy, A., Nagendran, J., and Michelakis, E.D. A
metabolic remodeling in right ventricular hypertrophy is
associated with decreased angiogenesis and a transition
from a compensated to a decompensated state in pulmo-
nary hypertension. J Mol Med 91, 1315, 2013.
23. Reddy, S., and Bernstein, D. The vulnerable right ventri-
cle. Curr Opin Pediatr 27, 563, 2015.
24. Ecarnot-Laubriet, A., Rochette, L., Vergely, C., Sicard, P.,
and Teyssier, J.R. The activation pattern of the antioxidant
enzymes in the right ventricle of rat in response to pres-
sure overload is of heart failure type. Heart Dis 5, 308,
2003.
25. Schreckenberg, R., Rebelo, M., Deten, A., Weber, M.,
Rohrbach, S., Pipicz, M., Csonka, C., Ferdinandy, P.,
Schulz, R., and Schluter, K.D. Specific mechanisms un-
derlying right heart failure: the missing upregulation of
superoxide dismutase-2 and its decisive role in anti-
oxidative defense. Antioxid Redox Signal 23, 1220, 2015.
26. Kaneko, S., Khoo, N.S., Smallhorn, J.F., and Tham, E.B.
Single right ventricles have impaired systolic and diastolic
function compared to those of left ventricular morphol-
ogy. J Am Soc Echocardiogr 25, 1222, 2012.
27. Kutty, S., Graney, B.A., Khoo, N.S., Li, L., Polak, A.,
Gribben, P., Hammel, J.M., Smallhorn, J.F., and Danford,
D.A. Serial assessment of right ventricular volume and
function in surgically palliated hypoplastic left heart
syndrome using real-time transthoracic three-dimensional
echocardiography. J Am Soc Echocardiogr 25, 682, 2012.
28. Sundareswaran, K.S., Kanter, K.R., Kitajima, H.D., Krish-
nankutty, R., Sabatier, J.F., Parks, W.J., Sharma, S., Yoga-
nathan,A.P., andFogel,M. Impairedpoweroutput and cardiac
index with hypoplastic left heart syndrome: a magnetic reso-
nance imaging study. Ann Thorac Surg 82, 1267, 2006.
29. Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M.,
Liao, R., Colucci, W.S., and Walsh, K. Disruption of
coordinated cardiac hypertrophy and angiogenesis con-
tributes to the transition to heart failure. J Clin Invest 115,
2108, 2005.
30. Anversa, P., Levicky, V., Beghi, C., McDonald, S.L., and
Kikkawa, Y. Morphometry of exercise-induced right
ventricular hypertrophy in the rat. Circ Res 52, 57, 1983.
31. Anversa, P., and Capasso, J.M. Loss of intermediate-sized
coronary-arteries and capillary proliferation after left-
ventricular failure in rats. Am J Physiol 260, H1552, 1991.
32. Garot, P., Teiger, E., Dupouy, P., Aptecar, E., Hittinger,
L., and Dubois-Rande, J.L. Coronary microcirculation and
cardiovascular pathology. Drugs 59 Spec No 1, 23, 1999.
33. Oka, T., Akazawa, H., Naito, A.T., and Komuro, I. An-
giogenesis and cardiac hypertrophy: maintenance of car-
diac function and causative roles in heart failure. Circ Res
114, 565, 2014.
34. Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo,
M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Har-
ada, M., Shimizu, I., Asahara, T., Hamada, H., Tomita, S.,
Molkentin, J.D., Zou, Y., and Komuro, I. p53-induced
inhibition of Hif-1 causes cardiac dysfunction during
pressure overload. Nature 446, 444, 2007.
35. van Deel, E.D., de Boer, M., Kuster, D.W., Boontje, N.M.,
Holemans, P., Sipido, K.R., van der Velden, J., and
Duncker, D.J. Exercise training does not improve cardiac
function in compensated or decompensated left ventricu-
lar hypertrophy induced by aortic stenosis. J Mol Cell
Cardiol 50, 1017, 2011.
464 CHERY ET AL.
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
36. Rakusan, K., Flanagan, M.F., Geva, T., Southern, J., and
Van Praagh, R. Morphometry of human coronary capil-
laries during normal growth and the effect of age in left
ventricular pressure-overload hypertrophy. Circulation 86,
38, 1992.
37. Pearlman, E.S., Weber, K.T., and Janicki, J.S. Quantita-
tive histology of the hypertrophied human heart. Fed Proc
40, 2042, 1981.
38. Friehs, I., Barillas, R., Vasilyev, N.V., Roy, N., McGo-
wan, F.X., and del Nido, P.J. Vascular endothelial growth
factor prevents apoptosis and preserves contractile func-
tion in hypertrophied infant heart. Circulation 114, I290,
2006.
39. Hoenig, M.R., Bianchi, C., Rosenzweig, A., and Sellke,
F.W. The cardiac microvasculature in hypertension, car-
diac hypertrophy and diastolic heart failure. Curr Vasc
Pharmacol 6, 292, 2008.
40. Lv, F.J., Tuan, R.S., Cheung, K.M., and Leung, V.Y.
Concise review: the surface markers and identity of human
mesenchymal stem cells. Stem Cells 32, 1408, 2014.
41. Burlacu, A., Grigorescu, G., Rosca, A.M., Preda, M.B.,
and Simionescu, M. Factors secreted by mesenchymal
stem cells and endothelial progenitor cells have comple-
mentary effects on angiogenesis in vitro. Stem Cells Dev
22, 643, 2013.
42. Hung, S.C., Pochampally, R.R., Chen, S.C., Hsu, S.C.,
and Prockop, D.J. Angiogenic effects of human multi-
potent stromal cell conditioned medium activate the
PI3K-Akt pathway in hypoxic endothelial cells to inhibit
apoptosis, increase survival, and stimulate angiogenesis.
Stem Cells 25, 2363, 2007.
43. Bronckaers, A., Hilkens, P., Martens, W., Gervois, P.,
Ratajczak, J., Struys, T., and Lambrichts, I. Mesenchymal
stem/stromal cells as a pharmacological and therapeutic
approach to accelerate angiogenesis. Pharmacol Therapeut
143, 181, 2014.
44. Carrion, B., Kong, Y.P., Kaigler, D., and Putnam, A.J.
Bone marrow-derived mesenchymal stem cells enhance
angiogenesis via their alpha 6 beta 1 integrin receptor.
Exp Cell Res 319, 2964, 2013.
45. Katare, R., Riu, F., Rowlinson, J., Lewis, A., Holden, R.,
Meloni, M., Reni, C., Wallrapp, C., Emanueli, C., and
Madeddu, P. Perivascular delivery of encapsulated mes-
enchymal stem cells improves postischemic angiogenesis
via paracrine activation of VEGF-A. Arterioscler Thromb
Vasc Biol 33, 1872, 2013.
46. Sadat, S., Gehmert, S., Song, Y.H., Yen, Y.S., Bai, X.W.,
Gaiser, S., Klein, H., and Alt, E. The cardioprotective effect
of mesenchymal stem cells is mediated by IGF-1 and
VEGF. Biochem Biophys Res Commun 363, 674, 2007.
47. Dufourcq, P., Descamps, B., Tojais, N.F., Leroux, L.,
Oses, P., Daret, D., Moreau, C., Lamaziere, J.M.D.,
Couffinhal, T., and Duplaa, C. Secreted frizzled-related
protein-1 enhances mesenchymal stem cell function in
angiogenesis and contributes to neovessel maturation.
Stem Cells 26, 2991, 2008.
48. Kuchroo, P., Dave, V., Vijayan, A., Viswanathan, C., and
Ghosh, D. Paracrine factors secreted by umbilical cord-
derived mscs induce angiogenesis in vitro by a VEGF-
independent pathway. Stem Cells Dev 24, 437, 2015.
49. Kong, P., Xie, X., Li, F., Liu, Y., and Lu, Y. Placenta
mesenchymal stem cell accelerates wound healing by
enhancing angiogenesis in diabetic Goto-Kakizaki (GK)
rats. Biochem Biophys Res Commun 438, 410, 2013.
50. Rahbarghazi, R., Nassiri, S.M., Khazraiinia, P., Kajbaf-
zadeh, A.M., Ahmadi, S.H., Mohammadi, E., Molazem,
M., and Zamani-Ahmadmahmudi, M. Juxtacrine and
Paracrine interactions of rat marrow-derived mesenchy-
mal stem cells, muscle-derived satellite cells, and neonatal
cardiomyocytes with endothelial cells in angiogenesis
dynamics. Stem Cells Dev 22, 855, 2013.
51. Mohammadi, E., Nassiri, S.M., Rahbarghazi, R., Siavashi,
V., and Araghi, A. Endothelial juxtaposition of distinct
adult stem cells activates angiogenesis signaling mole-
cules in endothelial cells. Cell Tissue Res 362, 597, 2015.
52. Shyu, K.G., Wang, B.W., Hung, H.F., Chang, C.C., and
Shih, D.T.B. Mesenchymal stem cells are superior to an-
giogenic growth factor genes for improving myocardial
performance in the mouse model of acute myocardial in-
farction. J Biomed Sci 13, 47, 2006.
53. Ikhapoh, I.A., Pelham, C.J., and Agrawal, D.K. Sry-type
HMG box 18 contributes to the differentiation of bone
marrow-derived mesenchymal stem cells to endothelial
cells. Differentiation 89, 87, 2015.
54. Qiu, X., Zhang, Y., Zhao, X., Zhang, S., Wu, J., Guo, H., and
Hu, Y. Enhancement of endothelial differentiation of adipose
derived mesenchymal stem cells by a three-dimensional
culture system of microwell. Biomaterials 53, 600, 2015.
55. Lu, W., Xiu, X., Zhao, Y., and Gui, M. Improved prolif-
eration and differentiation of bone marrow mesenchymal
stem cells into vascular endothelial cells with sphingosine
1-phosphate. Transplant Proc 47, 2035, 2015.
56. Konstanty-Kalandyk, J., Piatek, J., Miszalski-Jamka, T.,
Rudzinski, P., Walter, Z., Bartus, K., Urbanczyk-Zawadzka,
M., and Sadowski, J. The combined use of transmyocardial
laser revascularisation and intramyocardial injection of
bone-marrow derived stem cells in patients with end-stage
coronary artery disease: one year follow-up. Kardiol Pol 71,
485, 2013.
57. Gupta, P.K., Chullikana, A., Parakh, R., Desai, S., Das,
A., Gottipamula, S., Krishnamurthy, S., Anthony, N.,
Pherwani, A., and Majumdar, A.S. A double blind ran-
domized placebo controlled phase I/II study assessing the
safety and efficacy of allogeneic bone marrow derived
mesenchymal stem cell in critical limb ischemia. J Transl
Med 11, 143, 2013.
58. Mathiasen, A.B., Haack-Sorensen, M., Jorgensen, E., and
Kastrup, J. Autotransplantation of mesenchymal stromal
cells from bone-marrow to heart in patients with severe
stable coronary artery disease and refractory angina—final
3-year follow-up. Int J Cardiol 170, 246, 2013.
59. Lasala, G.P., Silva, J.A., and Minguell, J.J. Therapeutic
angiogenesis in patients with severe limb ischemia by
transplantation of a combination stem cell product. J
Thorac Cardiovasc Surg 144, 377, 2012.
60. Karantalis, V., DiFede, D.L., Gerstenblith, G., Pham, S.,
Symes, J., Zambrano, J.P., Fishman, J., Pattany, P.,
McNiece, I., Conte, J., Schulman, S., Wu, K., Shah, A.,
Breton, E., Davis-Sproul, J., Schwarz, R., Feigenbaum,
G., Mushtaq, M., Suncion, V.Y., Lardo, A.C., Borrello, I.,
Mendizabal, A., Karas, T.Z., Byrnes, J., Lowery, M.,
Heldman, A.W., and Hare, J.M. Autologous mesenchymal
stem cells produce concordant improvements in regional
function, tissue perfusion, and fibrotic burden when ad-
ministered to patients undergoing coronary artery bypass
grafting. Circ Res 114, 1302, 2014.
61. Heldman, A.W., DiFede, D.L., Fishman, J.E., Zambrano,
J.P., Trachtenberg, B.H., Karantalis, V., Mushtaq, M.,
REGENERATIVE MEDICINE AND HYPOPLASTIC LEFT HEART SYNDROME 465
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Williams, A.R., Suncion, V.Y., McNiece, I.K., Ghersin,
E., Soto, V., Lopera, G., Miki, R., Willens, H., Hendel, R.,
Mitrani, R., Pattany, P., Feigenbaum, G., Oskouei, B.,
Byrnes, J., Lowery, M.H., Sierra, J., Pujol, M.V., Delgado,
C., Gonzalez, P.J., Rodriguez, J.E., Bagno, L.L., Rouy, D.,
Altman, P., Foo, C.W.P., da Silva, J., Anderson, E.,
Schwarz, R., Mendizabal, A., and Hare, J.M. Transendo-
cardial Mesenchymal Stem Cells and Mononuclear Bone
Marrow Cells for Ischemic Cardiomyopathy The TAC-
HFT Randomized Trial. JAMA 311, 62, 2014.
62. Hess, D.C., Sila, C.A., Furlan, A.J., Wechsler, L.R.,
Switzer, J.A., and Mays, R.W. A double-blind placebo-
controlled clinical evaluation of MultiStem for the treat-
ment of ischemic stroke. Int J Stroke 9, 381, 2014.
63. George, R., and Lardo, A. Comparison of allogeneic vs
autologous bone marrow-derived mesenchymal stem cells
delivered by transendocardial injection in patients with
ischemic cardiomyopathy: the POSEIDON randomized
trial (vol. 308, pg 2369, 2012). JAMA 310, 750, 2013.
64. Lu, D.B., Chen, B., Liang, Z.W., Deng, W.Q., Jiang, Y.Z.,
Li, S.F., Xu, J., Wu, Q.N., Zhang, Z.H., Xie, B., and Chen,
S.H. Comparison of bone marrow mesenchymal stem cells
with bone marrow-derived mononuclear cells for treat-
ment of diabetic critical limb ischemia and foot ulcer: a
double-blind, randomized, controlled trial. Diabetes Res
Clin Pract 92, 26, 2011.
65. Chen, X.Q., Chen, L.L., Fan, L., Fang, J., Chen, Z.Y., and
Li, W.W. Stem cells with FGF4-bFGF fused gene en-
hances the expression of bFGF and improves myocardial
repair in rats. Biochem Biophys Res Commun 447, 145,
2014.
66. Han, Y., Tao, R., Han, Y., Sun, T., Chai, J., Xu, G., and
Liu, J. Microencapsulated VEGF gene-modified umbilical
cord mesenchymal stromal cells promote the vasculari-
zation of tissue-engineered dermis: an experimental study.
Cytotherapy 16, 160, 2014.
67. HoWangYin, K.Y., Loinard, C., Bakker, W., Guerin, C.L.,
Vilar, J., D’Audigier, C., Mauge, L., Bruneval, P.,
Emmerich, J., Levy, B.I., Pouyssegur, J., Smadja, D.M.,
and Silvestre, J.S. HIF-prolyl hydroxylase 2 inhibition
enhances the efficiency of mesenchymal stem cell-based
therapies for the treatment of critical limb ischemia. Stem
Cells 32, 231, 2014.
68. Zhang, T., Lee, Y.W., Rui, Y.F., Cheng, T.Y., and Li, G.
Bone marrow-derived mesenchymal stem cells promote
angiogenesis and growth of breast and prostate tumors.
Cytotherapy 15, S15, 2013.
69. Zhao, M.Z., Nonoguchi, N., Ikeda, N., Watanabe, T.,
Furutama, D., Miyazawa, D., Funakoshi, H., Kajimoto,
Y., Nakamura, T., Dezawa, M., Shibata, M.A., Otsuki, Y.,
Coffin, R.S., Liu, W.D., Kuroiwa, T., and Miyatake, S.
Novel therapeutic strategy for stroke in rats by bone
marrow stromal cells and ex vivo HGF gene transfer with
HSV-1 vector. J Cereb Blood Flow Metab 26, 1176, 2006.
70. Fierro, F.A., Kalomoiris, S., Sondergaard, C.S., and Nolta,
J.A. Effects on proliferation and differentiation of multi-
potent bone marrow stromal cells engineered to express
growth factors for combined cell and gene therapy. Stem
Cells 29, 1727, 2011.
71. Ma, J.L., Yang, F., Both, S.K., Prins, H.J., Helder, M.N.,
Pan, J.L., Cui, F.Z., Jansen, J.A., and van den Beucken,
J.J.J.P. In vitro and in vivo angiogenic capacity of BM-
MSCs/HUVECs and AT-MSCs/HUVECs cocultures.
Biofabrication 6, 015005, 2014.
72. Lin, R.Z., Moreno-Luna, R., Zhou, B., Pu, W.T., and
Melero-Martin, J.M. Equal modulation of endothelial cell
function by four distinct tissue-specific mesenchymal stem
cells. Angiogenesis 15, 443, 2012.
73. Arutyunyan, I., Fatkhudinov, T., Kananykhina, E., Usman,
N., Elchaninov, A., Makarov, A., Bolshakova, G., Gold-
shtein, D., and Sukhikh, G. Role of VEGF-A in angio-
genesis promoted by umbilical cord-derived mesenchymal
stromal/stem cells: in vitro study. Stem Cell Res Ther 7,
46, 2016.
74. Shen, C., Lie, P., Miao, T., Yu, M., Lu, Q., Feng, T., Li, J.,
Zu, T., Liu, X., and Li, H. Conditioned medium from
umbilical cord mesenchymal stem cells induces migration
and angiogenesis. Mol Med Rep 12, 20, 2015.
75. Kuchroo, P., Dave, V., Vijayan, A., Viswanathan, C., and
Ghosh, D. Paracrine factors secreted by umbilical cord-
derived mesenchymal stem cells induce angiogenesis
in vitro by a VEGF-independent pathway. Stem Cells Dev
24, 437, 2015.
76. Xie, N., Li, Z., Adesanya, T.M., Guo, W., Liu, Y., Fu, M.,
Kilic, A., Tan, T., Zhu, H., and Xie, X. Transplantation of
placenta-derived mesenchymal stem cells enhances an-
giogenesis after ischemic limb injury in mice. J Cell Mol
Med 20, 29, 2016.
77. Kinzer, M., Hingerl, K., Konig, J., Reinisch, A., Strunk,
D., Huppertz, B., and Lang, I. Mesenchymal stromal cells
from the human placenta promote neovascularization in a
mouse model in vivo. Placenta 35, 517, 2014.
78. Wang, S., Mundada, L., Johnson, S., Wong, J., Witt, R.,
Ohye, R.G., and Si, M.S. Characterization and angiogenic
potential of human neonatal and infant thymus mesen-
chymal stromal cells. Stem Cells Transl Med 4, 339, 2015.
79. Wang, S., Mundada, L., Colomb, E., Ohye, R.G., and Si,
M.S. Mesenchymal stem/stromal cells from discarded
neonatal sternal tissue: in vitro characterization and an-
giogenic properties. Stem Cells Int 2016, 5098747, 2016.
80. Choudhery, M.S., Khan, M., Mahmood, R., Mehmood, A.,
Khan, S.N., and Riazuddin, S. Bone marrow derived
mesenchymal stem cells from aged mice have reduced
wound healing, angiogenesis, proliferation and anti-
apoptosis capabilities. Cell Biol Int 36, 747, 2012.
81. Fan, M., Chen, W., Liu, W., Du, G.Q., Jiang, S.L., Tian,
W.C., Sun, L., Li, R.K., and Tian, H. The effect of age on
the efficacy of human mesenchymal stem cell transplan-
tation after a myocardial infarction. Rejuvenation Res 13,
429, 2010.
82. Khan, M., Mohsin, S., Khan, S.N., and Riazuddin, S.
Repair of senescent myocardium by mesenchymal stem
cells is dependent on the age of donor mice. J Cell Mol
Med 15, 1515, 2011.
83. Liu, X.B., Wang, J.A., Ji, X.Y., Yu, S.P., and Wei, L.
Preconditioning of bone marrow mesenchymal stem cells
by prolyl hydroxylase inhibition enhances cell survival
and angiogenesis in vitro and after transplantation into the
ischemic heart of rats. Stem Cell Res Ther 5, 111, 2014.
84. Herrmann, J.L., Wang, Y., Abarbanell, A.M., Weil, B.R.,
Tan, J.N., and Meldrum, D.R. Preconditioning mesen-
chymal stem cells with transforming growth factor-alpha
improves mesenchymal stem cell-mediated cardioprotec-
tion. Shock 33, 24, 2010.
85. Bader, A.M., Klose, K., Bieback, K., Korinth, D.,
Schneider, M., Seifert, M., Choi, Y.H., Kurtz, A., Falk, V.,
and Stamm, C. Hypoxic preconditioning increases sur-
vival and pro-angiogenic capacity of human cord blood
466 CHERY ET AL.
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
mesenchymal stromal cells in vitro. PLoS One 10,
e0138477, 2015.
86. Kang, H., Kim, K.H., Lim, J., Kim, Y.S., Heo, J., Choi, J.,
Jeong, J., Kim, Y., Kim, S.W., Oh, Y.M., Choo, M.S.,
Son, J., Kim, S.J., Yoo, H.J., Oh, W., Choi, S.J., Lee,
S.W., and Shin, D.M. The therapeutic effects of human
mesenchymal stem cells primed with sphingosine-1
phosphate on pulmonary artery hypertension. Stem Cells
Dev 24, 1658, 2015.
87. Huang, C.Y., Gu, H.M., Yu, Q., Manukyan, M.C., Poyn-
ter, J.A., and Wang, M.J. Sca-1+ cardiac stem cells me-
diate acute cardioprotection via paracrine factor SDF-1
following myocardial ischemia/reperfusion. PLoS One 6,
e29246, 2011.
88. Tseliou, E., Pollan, S., Malliaras, K., Terrovitis, J., Sun,
B.M., Galang, G., Marban, L., Luthringer, D., and Mar-
ban, E. Allogeneic cardiospheres safely boost cardiac
function and attenuate adverse remodeling after myocar-
dial infarction in immunologically mismatched rat strains.
J Am Coll Cardiol 61, 1108, 2013.
89. Cheng, K., Malliaras, K., Smith, R.R., Shen, D., Sun, B.,
Blusztajn, A., Xie, Y., Ibrahim, A., Aminzadeh, M.A.,
Liu, W., Li, T.S., De Robertis, M.A., Marban, L., Czer,
L.S., Trento, A., and Marban, E. Human cardiosphere-
derived cells from advanced heart failure patients exhibit
augmented functional potency in myocardial repair. JACC
Heart Fail 2, 49, 2014.
90. Hou, L., Kim, J.J., Woo, Y.J., and Huang, N.F. Stem cell-
based therapies to promote angiogenesis in ischemic car-
diovascular disease. Am J Physiol Heart Circ Physiol 310,
H455, 2016.
91. Nakanishi, C., Yamagishi, M., Yamahara, K., Hagino, I.,
Mori, H., Sawa, Y., Yagihara, T., Kitamura, S., and
Nagaya, N. Activation of cardiac progenitor cells through
paracrine effects of mesenchymal stem cells. Biochem
Biophys Res Commun 374, 11, 2008.
92. Kazakov, A., Meier, T., Werner, C., Hall, R., Klemmer,
B., Korbel, C., Lammert, F., Maack, C., Bohm, M., and
Laufs, U. C-kit(+) resident cardiac stem cells improve left
ventricular fibrosis in pressure overload. Stem Cell Res
15, 700, 2015.
93. Simpson, D.L., Mishra, R., Sharma, S., Goh, S.K.,
Deshmukh, S., and Kaushal, S. A strong regenerative
ability of cardiac stem cells derived from neonatal hearts.
Circulation 126, S46, 2012.
94. Maeng, Y.S., Kwon, J.Y., Kim, E.K., and Kwon, Y.G.
Heterochromatin protein 1 alpha (HP1alpha: CBX5) is a
key regulator in differentiation of endothelial progenitor
cells to endothelial Cells. Stem Cells 33, 1512, 2015.
95. Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta,
K., Link, A., Bohm, M., and Nickenig, G. Circulating
endothelial progenitor cells and cardiovascular outcomes.
N Engl J Med 353, 999, 2005.
96. Hoenig, M.R., Bianchi, C., and Sellke, F.W. Hypoxia
inducible factor-1 alpha, endothelial progenitor cells,
monocytes, cardiovascular risk, wound healing, cobalt and
hydralazine: a unifying hypothesis. Curr Drug Targets 9,
422, 2008.
97. Moon, J.H., Chae, M.K., Kim, K.J., Kim, H.M., Cha, B.S.,
Lee, H.C., Kim, Y.J., and Lee, B.W. Decreased endothe-
lial progenitor cells and increased serum glycated albumin
are independently correlated with plaque-forming carotid
artery atherosclerosis in type 2 diabetes patients without
documented ischemic disease. Circ J 76, 2273, 2012.
98. Fadini, G.P., Miorin, M., Facco, M., Bonamico, S.,
Baesso, I., Grego, F., Menegolo, M., de Kreutzenberg,
S.V., Tiengo, A., Agostini, C., and Avogaro, A. Circu-
lating endothelial progenitor cells are reduced in periph-
eral vascular complications of type 2 diabetes mellitus. J
Am Coll Cardiol 45, 1449, 2005.
99. Lee, F.Y., Chen, Y.L., Sung, P.H., Ma, M.C., Pei, S.N.,
Wu, C.J., Yang, C.H., Fu, M., Ko, S.F., Leu, S., and Yip,
H.K. Intracoronary transfusion of circulation-derived
CD34+ cells improves left ventricular function in pa-
tients with end-stage diffuse coronary artery disease
unsuitable for coronary intervention. Crit Care Med 43,
2117, 2015.
100. Atluri, P., Miller, J.S., Emery, R.J., Hung, G., Trubelja, A.,
Cohen, J.E., Lloyd, K., Han, J., Gaffey, A.C., MacArthur,
J.W., Chen, C.S., and Woo, Y.J. Tissue-engineered,
hydrogel-based endothelial progenitor cell therapy ro-
bustly revascularizes ischemic myocardium and pre-
serves ventricular function. J Thorac Cardiovasc Surg
148, 1090, 2014.
101. Finan, A., Kiedrowski, M., Turturice, B.A., Sopko, N.A.,
and Penn, M.S. Cardiac pressure overload initiates a
systemic stem cell response. Cytotherapy 14, 983, 2012.
102. Mueller, P., Kazakov, A., Semenov, A., Boehm, M., and
Laufs, U. Pressure-induced cardiac overload induces up-
regulation of endothelial and myocardial progenitor cells.
Cardiovasc Res 77, 151, 2008.
103. Oommen, S., Yamada, S., Peral, S.C., Campbell, K.A.,
Bruinsma, E.S., Terzic, A., and Nelson, T.J. Human um-
bilical cord blood-derived mononuclear cells improve
murine ventricular function upon intramyocardial delivery
in right ventricular chronic pressure overload. Stem Cell
Res Ther 6, 50, 2015.
104. Kim, S.W., Jin, H.L., Kang, S.M., Kim, S., Yoo, K.J.,
Jang, Y., Kim, H.O., and Yoon, Y.S. Therapeutic effects
of late outgrowth endothelial progenitor cells or mesen-
chymal stem cells derived from human umbilical cord
blood on infarct repair. Int J Cardiol 203, 498, 2016.
105. Padalino, M.A., Quarti, A., Angeli, E., Frigo, A.C., Vida,
V.L., Pozzi, M., Gargiulo, G., and Stellin, G. Early and
mid-term clinical experience with extracellular matrix
scaffold for congenital cardiac and vascular reconstructive
surgery: a multicentric Italian studydagger. Interact Car-
diovasc Thorac Surg 21, 40, 2015.
106. Rosario-Quinones, F., Magid, M.S., Yau, J., Pawale, A.,
and Nguyen, K. Tissue reaction to porcine intestinal
Submucosa (CorMatrix) implants in pediatric cardiac pa-
tients: a single-center experience. Ann Thorac Surg 99,
1373, 2015.
107. Ramos, C.M., Francisco, J.C., Olandoski, M., Carvalho,
K.A., Cunha, R., Erbano, B.O., Jorge, L.F., Baena, C.P.,
Amaral, V.F., Noronha, L., Macedo, R.M., Faria-Neto,
J.R., and Guarita-Souza, L.C. Myocardial regeneration
after implantation of porcine small intestinal submucosa
in the left ventricle. Rev Bras Cir Cardiovasc 29, 202,
2014.
108. Witt, R.G., Raff, G., Van Gundy, J., Rodgers-Ohlau, M.,
and Si, M.S. Short-term experience of porcine small in-
testinal submucosa patches in paediatric cardiovascular
surgery. Eur J Cardiothorac Surg 44, 72, 2013.
109. Hodonsky, C., Mundada, L., Wang, S., Witt, R., Raff, G.,
Kaushal, S., and Si, M.S. Effects of scaffold material used
in cardiovascular surgery on mesenchymal stem cells and
cardiac progenitor cells. Ann Thorac Surg 99, 605, 2015.
REGENERATIVE MEDICINE AND HYPOPLASTIC LEFT HEART SYNDROME 467
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
110. Okada, M., Payne, T.R., Oshima, H., Momoi, N., Tobita,
K., and Huard, J. Differential efficacy of gels derived from
small intestinal submucosa as an injectable biomaterial for
myocardial infarct repair. Biomaterials 31, 7678, 2010.
111. Slaughter, M.S., Soucy, K.G., Matheny, R.G., Lewis,
B.C., Hennick, M.F., Choi, Y., Monreal, G., Sobieski,
M.A., Giridharan, G.A., and Koenig, S.C. Development of
an extracellular matrix delivery system for effective in-
tramyocardial injection in ischemic tissue. ASAIO J 60,
730, 2014.
112. Toeg, H.D., Tiwari-Pandey, R., Seymour, R., Ahmadi, A.,
Crowe, S., Vulesevic, B., Suuronen, E.J., and Ruel, M.
Injectable small intestine submucosal extracellular matrix
in an acute myocardial infarction model. Ann Thorac Surg
96, 1686, 2013.
113. Johnson, T.D., Braden, R.L., and Christman, K.L. In-
jectable ECM scaffolds for cardiac repair. Methods Mol
Biol 1181, 109, 2014.
114. Song, M., Jang, H., Lee, J., Kim, J.H., Kim, S.H., Sun, K.,
and Park, Y. Regeneration of chronic myocardial infarc-
tion by injectable hydrogels containing stem cell homing
factor SDF-1 and angiogenic peptide Ac-SDKP. Bioma-
terials 35, 2436, 2014.
115. Abdalla, S., Makhoul, G., Duong, M., Chiu, R.C., and
Cecere, R. Hyaluronic acid-based hydrogel induces neo-
vascularization and improves cardiac function in a rat
model of myocardial infarction. Interact Cardiovasc
Thorac Surg 17, 767, 2013.
116. MacArthur, J.W., Jr., Purcell, B.P., Shudo, Y., Cohen,
J.E., Fairman, A., Trubelja, A., Patel, J., Hsiao, P., Yang,
E., Lloyd, K., Hiesinger, W., Atluri, P., Burdick, J.A., and
Woo, Y.J. Sustained release of engineered stromal cell-
derived factor 1-alpha from injectable hydrogels effec-
tively recruits endothelial progenitor cells and preserves
ventricular function after myocardial infarction. Circula-
tion 128, S79, 2013.
117. Chiu, L.L., Reis, L.A., Momen, A., and Radisic, M.
Controlled release of thymosin beta4 from injected
collagen-chitosan hydrogels promotes angiogenesis and
prevents tissue loss after myocardial infarction. Regen
Med 7, 523, 2012.
118. Salimath, A.S., Phelps, E.A., Boopathy, A.V., Che, P.L.,
Brown, M., Garcia, A.J., and Davis, M.E. Dual delivery of
hepatocyte and vascular endothelial growth factors via a
protease-degradable hydrogel improves cardiac function
in rats. PLoS One 7, e50980, 2012.
119. Lob, H.E., Marvar, P.J., Guzik, T.J., Sharma, S., McCann,
L.A., Weyand, C., Gordon, F.J., and Harrison, D.G. In-
duction of hypertension and peripheral inflammation by
reduction of extracellular superoxide dismutase in the
central nervous system. Hypertension 55, 277, 2010.
120. Laurila, J.P., Laatikainen, L.E., Castellone, M.D., and
Laukkanen, M.O. SOD3 reduces inflammatory cell mi-
gration by regulating adhesion molecule and cytokine
expression. PLoS One 4, e5786, 2009.
121. Rabbani, Z.N., Anscher, M.S., Folz, R.J., Archer, E.,
Huang, H., Chen, L., Golson, M.L., Samulski, T.S., De-
whirst, M.W., and Vujaskovic, Z. Overexpression of ex-
tracellular superoxide dismutase reduces acute radiation
induced lung toxicity. BMC Cancer 5, 59, 2005.
122. Yang, Z., von Ballmoos, M.W., Faessler, D., Voelzmann,
J., Ortmann, J., Diehm, N., Kalka-Moll, W., Baumgartner,
I., Di Santo, S., and Kalka, C. Paracrine factors secreted
by endothelial progenitor cells prevent oxidative stress-
induced apoptosis of mature endothelial cells. Athero-
sclerosis 211, 103, 2010.
123. Cheng, Y., Guo, S., Liu, G., Feng, Y., Yan, B., Yu, J.,
Feng, K., and Li, Z. Transplantation of bone marrow-
derived endothelial progenitor cells attenuates myo-
cardial interstitial fibrosis and cardiac dysfunction in
streptozotocin-induced diabetic rats. Int J Mol Med 30,
870, 2012.
124. Qiu, J., Li, W., Feng, S., Wang, M., and He, Z. Trans-
plantation of bone marrow-derived endothelial progenitor
cells attenuates cerebral ischemia and reperfusion injury
by inhibiting neuronal apoptosis, oxidative stress and
nuclear factor-kappaB expression. Int J Mol Med 31, 91,
2013.
125. DeSantiago, J., Bare, D.J., and Banach, K. Ischemia/Re-
perfusion injury protection by mesenchymal stem cell
derived antioxidant capacity. Stem Cells Dev 22, 2497,
2013.
126. Arslan, F., Lai, R.C., Smeets, M.B., Akeroyd, L., Choo,
A., Aguor, E.N., Timmers, L., van Rijen, H.V., Doe-
vendans, P.A., Pasterkamp, G., Lim, S.K., and de Kleijn,
D.P. Mesenchymal stem cell-derived exosomes increase
ATP levels, decrease oxidative stress and activate PI3K/
Akt pathway to enhance myocardial viability and prevent
adverse remodeling after myocardial ischemia/reperfusion
injury. Stem Cell Res 10, 301, 2013.
127. Pan, Q., Qin, X., Ma, S., Wang, H., Cheng, K., Song, X.,
Gao, H., Wang, Q., Tao, R., Wang, Y., Li, X., Xiong, L.,
and Cao, F. Myocardial protective effect of extracellular
superoxide dismutase gene modified bone marrow mes-
enchymal stromal cells on infarcted mice hearts. Ther-
anostics 4, 475, 2014.
128. Zimmermann, W.H., and Cesnjevar, R. Cardiac tissue
engineering: implications for pediatric heart surgery. Pe-
diatr Cardiol 30, 716, 2009.
129. Hartman, M.E., Dai, D.F., and Laflamme, M.A. Human
pluripotent stem cells: prospects and challenges as a
source of cardiomyocytes for in vitro modeling and cell-
based cardiac repair. Adv Drug Deliv Rev 96, 3, 2016.
130. Sekine, H., Shimizu, T., Hobo, K., Sekiya, S., Yang, J.,
Yamato, M., Kurosawa, H., Kobayashi, E., and Okano, T.
Endothelial cell coculture within tissue-engineered cardi-
omyocyte sheets enhances neovascularization and im-
proves cardiac function of ischemic hearts. Circulation
118, S145, 2008.
131. Tulloch, N.L., Muskheli, V., Razumova, M.V., Korte,
F.S., Regnier, M., Hauch, K.D., Pabon, L., Reinecke, H.,
and Murry, C.E. Growth of engineered human myocar-
dium with mechanical loading and vascular coculture.
Circ Res 109, 47, 2011.
132. Patra, C., Boccaccini, A.R., and Engel, F.B. Vascularisa-
tion for cardiac tissue engineering: the extracellular ma-
trix. Thromb Haemost 113, 532, 2015.
133. Sun, X., Altalhi, W., and Nunes, S.S. Vascularization
strategies of engineered tissues and their application in
cardiac regeneration. Adv Drug Deliv Rev 96, 183, 2016.
134. Lesman, A., Gepstein, L., and Levenberg, S. Cell tri-
culture for cardiac vascularization. Methods Mol Biol
1181, 131, 2014.
135. Coulombe, K.L.K., Bajpai, V.K., Andreadis, S.T., and
Murry, C.E. Heart Regeneration with engineered myo-
cardial tissue. Annu Rev Biomed Eng 16, 1, 2014.
136. Ott, H.C., Matthiesen, T.S., Goh, S.K., Black, L.D., Kren,
S.M., Netoff, T.I., and Taylor, D.A. Perfusion-decellularized
468 CHERY ET AL.
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
matrix: using nature’s platform to engineer a bioartificial
heart. Nat Med 14, 213, 2008.
137. Guyette, J.P., Charest, J.M., Mills, R.W., Jank, B.J., Moser,
P.T., Gilpin, S.E., Gershlak, J.R., Okamoto, T., Gonzalez,
G., Milan, D.J., Gaudette, G.R., and Ott, H.C. Bioengi-
neering human myocardium on native extracellular ma-
trix. Circ Res 118, 56, 2016.
138. Sekine, H., Shimizu, T., Sakaguchi, K., Dobashi, I., Wada,
M., Yamato, M., Kobayashi, E., Umezu, M., and Okano,
T. In vitro fabrication of functional three-dimensional
tissues with perfusable blood vessels. Nat Commun 4,
1399, 2013.
139. Moya, M.L., Hsu, Y.H., Lee, A.P., Hughes, C.C.W., and
George, S.C. In vitro perfused human capillary networks.
Tissue Eng Part C Methods 19, 730, 2013.
140. Lee, V.K., Lanzi, A.M., Ngo, H., Yoo, S.S., Vincent, P.A.,
and Dai, G.H. Generation of multi-scale vascular network
system within 3D hydrogel using 3D bio-printing tech-
nology. Cell Mol Bioeng 7, 460, 2014.
141. Kurokawa, Y.K., and George, S.C. Tissue engineering the
cardiac microenvironment: multicellular microphysiological
systems for drug screening. Adv Drug Deliv Rev 96, 225,
2016.
142. Nadal-Ginard, B., Kajstura, J., Anversa, P., and Leri, A. A
matter of life and death: cardiac myocyte apoptosis and
regeneration. J Clin Invest 111, 1457, 2003.
143. Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W.,
Nitahara, J.A., Quaini, E., Di Loreto, C., Beltrami, C.A.,
Krajewski, S., Reed, J.C., and Anversa, P. Apoptosis in
the failing human heart. N Engl J Med 336, 1131, 1997.
144. Bearzi, C., Rota, M., Hosoda, T., Tillmanns, J., Nascim-
bene, A., De Angelis, A., Yasuzawa-Amano, S., Trofi-
mova, I., Siggins, R.W., Lecapitaine, N., Cascapera, S.,
Beltrami, A.P., D’Alessandro, D.A., Zias, E., Quaini, F.,
Urbanek, K., Michler, R.E., Bolli, R., Kajstura, J., Leri,
A., and Anversa, P. Human cardiac stem cells. Proc Natl
Acad Sci U S A 104, 14068, 2007.
145. Bolli, R., Chugh, A.R., D’Amario, D., Loughran, J.H.,
Stoddard, M.F., Ikram, S., Beache, G.M., Wagner, S.G.,
Leri, A., Hosoda, T., Sanada, F., Elmore, J.B., Goichberg,
P., Cappetta, D., Solankhi, N.K., Fahsah, I., Rokosh, D.G.,
Slaughter, M.S., Kajstura, J., and Anversa, P. Cardiac
stem cells in patients with ischaemic cardiomyopathy
(SCIPIO): initial results of a randomised phase 1 trial.
Lancet 378, 1847, 2011.
146. Loughran, J.H., Elmore, J.B., Waqar, M., Chugh, A.R.,
and Bolli, R. Cardiac stem cells in patients with ischemic
cardiomyopathy: discovery, translation, and clinical in-
vestigation. Curr Atheroscler Rep 14, 491, 2012.
147. Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K.,
Thomson, L.E., Berman, D., Czer, L.S., Marban, L.,
Mendizabal, A., Johnston, P.V., Russell, S.D., Schuleri,
K.H., Lardo, A.C., Gerstenblith, G., and Marban, E.
Intracoronary cardiosphere-derived cells for heart re-
generation after myocardial infarction (CADUCEUS): a
prospective, randomised phase 1 trial. Lancet 379, 895,
2012.
148. Kaushal, S., and Wehman, B. Stem cells on a new stage:
treatment of hypoplastic left heart syndrome. J Thorac
Cardiovasc Surg 150, 1209, 2015.
149. Tarui, S., Ishigami, S., Ousaka, D., Kasahara, S., Ohtsuki,
S., Sano, S., and Oh, H. Transcoronary infusion of cardiac
progenitor cells in hypoplastic left heart syndrome: three-
year follow-up of the Transcoronary Infusion of Cardiac
Progenitor Cells in Patients With Single-Ventricle Phy-
siology (TICAP) trial. J Thorac Cardiovasc Surg 150,
1198, 2015.
150. Ishigami, S., Ohtsuki, S., Tarui, S., Ousaka, D., Eitoku, T.,
Kondo,M., Okuyama, M., Kobayashi, J., Baba, K., Arai, S.,
Kawabata, T., Yoshizumi, K., Tateishi, A., Kuroko, Y.,
Iwasaki, T., Sato, S., Kasahara, S., Sano, S., and Oh, H.
Intracoronary autologous cardiac progenitor cell transfer in
patients with hypoplastic left heart syndrome: the TICAP
prospective phase 1 controlled trial. CircRes116,653, 2015.
151. Tarui, S., Sano, S., and Oh, H. Stem cell therapies in
patients with single ventricle physiology. Methodist De-
bakey Cardiovasc J 10, 77, 2014.
152. Bergmane, I., Lacis, A., Lubaua, I., Jakobsons, E., and
Erglis, A. Follow-up of the patients after stem cell trans-
plantation for pediatric dilated cardiomyopathy. Pediatr
Transplant 17, 266, 2013.
153. Rupp, S., Bauer, J., Tonn, T., Schachinger, V., Dimmeler,
S., Zeiher, A.M., and Schranz, D. Intracoronary admin-
istration of autologous bone marrow-derived progenitor
cells in a critically ill two-yr-old child with dilated car-
diomyopathy. Pediatr Transplant 13, 620, 2009.
154. Rupp, S., Zeiher, A.M., Dimmeler, S., Tonn, T., Bauer, J.,
Jux, C., Akintuerk, H., and Schranz, D. A regenerative
strategy for heart failure in hypoplastic left heart syn-
drome: intracoronary administration of autologous bone
marrow-derived progenitor cells. J Heart Lung Transplant
29, 574, 2010.
155. Burkhart, H.M., Qureshi, M.Y., Peral, S.C., O’Leary,
P.W., Olson, T.M., Cetta, F., Nelson, T.J., and Wanek
Program Clinical Pipeline, G. Regenerative therapy for
hypoplastic left heart syndrome: first report of in-
traoperative intramyocardial injection of autologous
umbilical-cord blood-derived cells. J Thorac Cardiovasc
Surg 149, e35, 2015.
Address correspondence to:
Ming-Sing Si, MD
Department of Cardiac Surgery
University of Michigan
C.S. Mott Children’s Hospital
1540 E. Hospital Drive, SPC 4204
Floor 11, Room 735
Ann Arbor, MI 48109-4204
E-mail: mingsing@umich.edu
Received: April 7, 2016
Accepted: May 26, 2016
Online Publication Date: June 29, 2016
REGENERATIVE MEDICINE AND HYPOPLASTIC LEFT HEART SYNDROME 469
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
This article has been cited by:
1. Hyokyoung Kwon, Minjeong Kim, Yunmi Seo, Yae Seul Moon, Hwa Jeong Lee, Kyuri Lee, Hyukjin Lee. 2018. Emergence of
synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials 156, 172-193. [Crossref]
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
